ATE518888T1 - Stabilisierte lösung mit hoher igm-konzentration - Google Patents
Stabilisierte lösung mit hoher igm-konzentrationInfo
- Publication number
- ATE518888T1 ATE518888T1 AT04792204T AT04792204T ATE518888T1 AT E518888 T1 ATE518888 T1 AT E518888T1 AT 04792204 T AT04792204 T AT 04792204T AT 04792204 T AT04792204 T AT 04792204T AT E518888 T1 ATE518888 T1 AT E518888T1
- Authority
- AT
- Austria
- Prior art keywords
- stabilized solution
- high igm
- igm concentration
- solutions
- igm
- Prior art date
Links
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 abstract 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 229960003589 arginine hydrochloride Drugs 0.000 abstract 1
- -1 cationic ion Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910001629 magnesium chloride Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003351388 | 2003-10-09 | ||
PCT/JP2004/014935 WO2005035574A1 (ja) | 2003-10-09 | 2004-10-08 | IgM高濃度安定化溶液 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE518888T1 true ATE518888T1 (de) | 2011-08-15 |
Family
ID=34431075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04792204T ATE518888T1 (de) | 2003-10-09 | 2004-10-08 | Stabilisierte lösung mit hoher igm-konzentration |
Country Status (5)
Country | Link |
---|---|
US (2) | US20070212346A1 (de) |
EP (1) | EP1688432B1 (de) |
JP (1) | JP4762717B2 (de) |
AT (1) | ATE518888T1 (de) |
WO (1) | WO2005035574A1 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004256354B2 (en) | 2003-07-15 | 2011-07-07 | Chugai Seiyaku Kabushiki Kaisha | IgM production by transformed cells and methods for quantifying said IgM production |
US7803914B2 (en) | 2003-10-09 | 2010-09-28 | Chugai Seiyaku Kabushiki Kaisha | Methods for stabilizing protein solutions |
WO2005035574A1 (ja) | 2003-10-09 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | IgM高濃度安定化溶液 |
EP1962907A2 (de) * | 2005-12-21 | 2008-09-03 | Wyeth a Corporation of the State of Delaware | Proteinformulierungen mit verminderter viskosität und anwendungen davon |
KR101522036B1 (ko) * | 2006-12-05 | 2015-05-20 | 크루셀 홀란드 비.브이. | 액체 항-광견병 항체 조성물 |
CN101679507A (zh) * | 2007-03-29 | 2010-03-24 | 艾博特公司 | 结晶抗人类il-12抗体 |
EP2331078B1 (de) * | 2008-08-27 | 2012-09-19 | Merck Sharp & Dohme Corp. | Lyophilisierte formulierungen von gentechnisch veränderten anti-il-23p19-antikörpern |
AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
KR20120115383A (ko) * | 2010-01-29 | 2012-10-17 | 가부시키가이샤 아크시스 | 변형성 관절증 치료 또는 예방용 의약 조성물 및 이의 제조 방법 |
MX2012012743A (es) * | 2010-05-03 | 2012-11-23 | Genentech Inc | Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina. |
EP2471554A1 (de) | 2010-12-28 | 2012-07-04 | Hexal AG | Pharmazeutische Formulierung mit biopharmazeutischem Arzneimittel |
FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
CN110913906A (zh) | 2017-05-02 | 2020-03-24 | 默沙东公司 | 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂 |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
CA3183021A1 (en) * | 2020-07-10 | 2022-01-13 | Myles Lindsay | Method for obtaining a composition comprising human plasma-derived immunoglobulin m |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5157113A (en) * | 1987-08-10 | 1992-10-20 | Miles Inc. | Removal of nucleic acids from monoclonal antibody preparations |
EP0303088B1 (de) * | 1987-08-10 | 1992-11-11 | Miles Inc. | Gereinigtes IgM |
GB8719963D0 (en) | 1987-08-24 | 1987-09-30 | Cattaneo A | Recombinant dna products |
US6238891B1 (en) | 1987-11-18 | 2001-05-29 | Cetus Oncology Corporation | Method of increasing product expression through solute stress |
CA1312030C (en) | 1987-11-18 | 1992-12-29 | Brian Maiorella | Method to increase antibody titer |
JP2501116B2 (ja) | 1988-03-05 | 1996-05-29 | 日本電信電話株式会社 | 巡回制御形回線交換方法 |
DE3825429C2 (de) * | 1988-07-27 | 1994-02-10 | Biotest Pharma Gmbh | Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt |
FR2655341B1 (fr) * | 1989-12-01 | 1992-02-21 | Rhone Poulenc Sante | Derives dihydropyranniques, leurs procedes de preparation et leur utilisation. |
GB9010944D0 (en) | 1990-05-16 | 1990-07-04 | Central Blood Lab Authority | Chemical compounds |
US5419904A (en) | 1990-11-05 | 1995-05-30 | The Regents Of The University Of California | Human B-lymphoblastoid cell line secreting anti-ganglioside antibody |
JPH05192181A (ja) | 1990-12-18 | 1993-08-03 | Ishihara Sangyo Kaisha Ltd | ヒトモノクローナル抗体 |
EP0492409A1 (de) | 1990-12-18 | 1992-07-01 | Ishihara Sangyo Kaisha, Ltd. | Menschlicher monoklonaler Antikörper |
JPH0565233A (ja) * | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
DE69231135T2 (de) | 1991-03-12 | 2001-02-15 | Biogen Inc | CD2 bindender Bereich für das Lymphocyten-Funktion assoziierte Antigen-3 |
JPH04360696A (ja) | 1991-06-06 | 1992-12-14 | Sumitomo Chem Co Ltd | 新規なヒトbリンパ細胞株を宿主として産生された組み換えヒト抗体 |
GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
JP3565572B2 (ja) | 1992-09-07 | 2004-09-15 | 協和醗酵工業株式会社 | ヒト化抗体 |
US5830470A (en) | 1992-09-07 | 1998-11-03 | Kyowa Hakko Kogyo Co., Ltd. | Humanized antibodies to ganglioside GM2 |
JPH06178689A (ja) | 1992-12-11 | 1994-06-28 | Mitsui Toatsu Chem Inc | I型緑膿菌を抗原とするヒト抗体をコードする遺伝子 |
JPH06189781A (ja) | 1992-12-25 | 1994-07-12 | Mitsui Toatsu Chem Inc | 培養液中の生理活性タンパク質の安定化方法 |
JPH09127112A (ja) * | 1995-10-30 | 1997-05-16 | Dainabotsuto Kk | 修飾IgM免疫学的測定試薬 |
JPH09127114A (ja) * | 1995-11-01 | 1997-05-16 | Dainabotsuto Kk | 免疫学的測定用安定化IgM試薬 |
DK0935607T3 (da) | 1996-08-16 | 2004-12-06 | Harvard College | Oplöselige monovalente og multivalente MHC klasse II-fusionsproteiner samt anvendelser deraf |
EP0835880A1 (de) * | 1996-10-14 | 1998-04-15 | Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk | Verfahren zur Herstellung eines IgM Präparates für die intravenöse Applikation |
JPH10324699A (ja) | 1997-03-21 | 1998-12-08 | Sankyo Co Ltd | 抗ヒトFasヒト化抗体 |
US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
AU3544599A (en) | 1998-01-16 | 1999-08-02 | Paul E. Borchardt | Use of radiolabeled monoclonal igm in therapy for cancer and autoimmune disease |
AU2444899A (en) | 1998-01-22 | 1999-08-09 | Astrazeneca Ab | Pharmaceutical formulation comprising an antibody and a citrate buffer |
JP2002504342A (ja) | 1998-02-19 | 2002-02-12 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 一価mhc結合ドメイン融合タンパク質および接合体、多価mhc結合ドメイン融合タンパク質および接合体、ならびに多量体mhc結合ドメイン融合タンパク質および接合体、そしてそれらのための使用 |
JP2000154149A (ja) | 1998-09-18 | 2000-06-06 | Sankyo Co Ltd | 抗ヒトFasヒト化抗体含有抗リウマチ剤 |
CZ300762B6 (cs) | 1998-10-16 | 2009-08-05 | Biogen Idec Ma Inc. | Fúzní proteiny interferonu-beta-1a a jejich použití |
EP2275540B1 (de) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Verfahren zur Steuerung der Aktivität von immunologisch funktionellen Molekülen |
EP1174148A4 (de) | 1999-04-28 | 2005-05-04 | Yamanouchi Pharma Co Ltd | Parenterale medizinische zusammensetzungen enthaltend fragmente humanisierter monoklonaler antikörper und methode zur stabilisierung derselben |
WO2001023431A1 (fr) | 1999-09-30 | 2001-04-05 | Kyowa Hakko Kogyo Co., Ltd. | Derives d'anticorps contre le ganglioside gm2 |
EP1226752A4 (de) | 1999-11-05 | 2004-05-06 | Kyowa Hakko Kogyo Kk | Transgene nicht-humane tiere zur überwachung einer veränderung der kalzium-ionenkonzentration in zellen |
SI2857516T1 (sl) | 2000-04-11 | 2017-09-29 | Genentech, Inc. | Multivalentna protitelesa in njihove uporabe |
WO2002010371A1 (fr) | 2000-08-01 | 2002-02-07 | Kyowa Hakko Kogyo Co., Ltd. | Peptide acitf sur le plan physiologique et utilisation de celui-ci |
GB0113179D0 (en) | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
JP2003128576A (ja) | 2001-10-25 | 2003-05-08 | Taisho Pharmaceut Co Ltd | エンドトキシン誘発性疾患治療薬 |
AU2002356749A1 (en) | 2001-11-28 | 2003-06-10 | Hermann Katinger | Process for the production of polypeptides in mammalian cell cultures |
AU2004256354B2 (en) | 2003-07-15 | 2011-07-07 | Chugai Seiyaku Kabushiki Kaisha | IgM production by transformed cells and methods for quantifying said IgM production |
US7803914B2 (en) * | 2003-10-09 | 2010-09-28 | Chugai Seiyaku Kabushiki Kaisha | Methods for stabilizing protein solutions |
WO2005035574A1 (ja) | 2003-10-09 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | IgM高濃度安定化溶液 |
-
2004
- 2004-10-08 WO PCT/JP2004/014935 patent/WO2005035574A1/ja active Application Filing
- 2004-10-08 AT AT04792204T patent/ATE518888T1/de not_active IP Right Cessation
- 2004-10-08 JP JP2005514615A patent/JP4762717B2/ja not_active Expired - Fee Related
- 2004-10-08 EP EP04792204A patent/EP1688432B1/de not_active Not-in-force
- 2004-10-08 US US10/575,192 patent/US20070212346A1/en not_active Abandoned
-
2009
- 2009-07-24 US US12/509,075 patent/US8920797B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US8920797B2 (en) | 2014-12-30 |
US20070212346A1 (en) | 2007-09-13 |
EP1688432B1 (de) | 2011-08-03 |
JP4762717B2 (ja) | 2011-08-31 |
EP1688432A4 (de) | 2007-09-12 |
JPWO2005035574A1 (ja) | 2008-02-14 |
EP1688432A1 (de) | 2006-08-09 |
WO2005035574A1 (ja) | 2005-04-21 |
US20090285802A1 (en) | 2009-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE518888T1 (de) | Stabilisierte lösung mit hoher igm-konzentration | |
EA201391317A1 (ru) | Стабильная композиция хлорноватистой кислоты, способы ее получения и применение | |
BR112015031831A2 (pt) | composição de nucleação e composição polimérica termoplástica compreendendo tal composição de nucleação | |
DK1819686T3 (da) | 5-Hydroxybenzothiazolderivater med beta2-adrenoreceptoragonistaktivitet | |
EP3778599A3 (de) | Pestizid wirksame bi- oder tricyclische heterocyclen mit schwefelhaltigen substituenten | |
BR112013025732A2 (pt) | composto de imidazo-oxazina ou sal do mesmo | |
UA114597C2 (uk) | Офтальмологічна композиція з високою концентрацією олопатадину | |
EA201000089A1 (ru) | Применение гомо- и сополимеров для стабилизации составов активных ингредиентов | |
BR112015002153A2 (pt) | composto heterocíclico parcialmente saturado contendo nitrogênio | |
TW200633951A (en) | Method for reducing cyclohexenone content of a cyclohexenone-containing organic mixture | |
PL2397510T3 (pl) | Wysoko stężone granulowane dodatki do polimerów w postaci koncentratów | |
BR112015013430A2 (pt) | método de aprimoramento da compatibilidade de uma solução herbicida aquosa; solução herbicida aquosa com compatibilidade aprimorada; e composição herbicida secante | |
MX2015016424A (es) | Soluciones acuosas que contienen un agente complejante de alto grado de concentracion. | |
BR112014032563A2 (pt) | composto de amida e uso do mesmo para controle de peste | |
SG179405A1 (en) | Additive for polishing composition | |
DK1458744T3 (da) | Fremgangsmåde til renaturering af proteiner | |
EP4293116A3 (de) | Stabiles flüssiges fibrinogen | |
GB2422167B (en) | Viscoelastic surfactant gels with reduced salt concentration | |
DE502007005301D1 (de) | Verbindungen enthaltend organofluorochlorophosphatanionen | |
SG159481A1 (en) | Stabilization of thermolysin in aqueous solution | |
ATE391933T1 (de) | Elektrobenetzungssystem mit elektrolytlösung von hoher zuverlässigkeit | |
RU2009106499A (ru) | Оптический монокристалл | |
DE502005008793D1 (de) | Salze mit alkoxytris(fluoralkyl)borat-anionen | |
RU2010145968A (ru) | Антиэймериозная фармацевтическая композиция на основе соли четвертичного фосфония и замещенного динитробензофуроксана | |
BR112013024985A2 (pt) | composições de controle de hematologia com estabilidade prolongada |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |